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ABSTRACT   
Objective:  To identify modifiable factors associated with sessile serrated polyps (SSPs), and 
compare the association of these factors to conventional adenomas (ADs) and hyperplastic 
polyps (HPs). 
Design:  We utilized data from the Tennessee Colorectal Polyp Study, a colonoscopy-based 
case-control study.  Included were 214 SSP cases, 1779 AD cases, 560 HP cases and 3851 
polyp-free controls.  
Results:  Cigarette smoking was associated with increased risk for all polyps and was stronger 
for SSPs than for ADs (OR 1.74. 95% CI: 1.16-2.62, for current vs. never, ptrend=0.008). Current 
regular use of nonsteroidal anti-inflammatories (NSAID) was associated with a 40% reduction in 
SSPs risk in comparison to never-users (OR 0.68, 95% CI 0.48-0.96, ptrend=0.03), similar to the 
association with AD. Red meat intake was strongly associated with SSPs risk (OR 2.59, 95% CI 
1.41-4.74 for highest vs. lowest intake, ptrend<0.001) and the association with SSP was stronger 
than with AD (ptrend=0.003). Obesity, folate intake, fiber intake, and fat intake were not 
associated with SSP risk after adjustment for other factors. Exercise, alcohol use, and calcium 
intake were not associated with risk for SSPs.  
Conclusion:  SSPs share some modifiable risk factors for ADs, some of which are more 
strongly associated with SSPs than ADs. Thus, preventive efforts to reduce risk for ADs may 
also be applicable to SSPs. Additionally, SSPs have some distinctive risk factors.  Future 
studies should evaluate the preventive strategies for these factors. The findings from this study 
also contribute to an understanding of the etiology and biology of SSPs. 
 
SUMMARY 
What is already known about this subject? 
• Most colorectal cancers are derived from two separate precursor pathways: a 
conventional adenoma-carcinoma pathway and a serrated pathway. 
• Lifestyle factors such as cigarette smoking and increased red meat intake are known risk 
factors for conventional colorectal adenomas. 
• Risk factors for sessile serrated polyps are less known, given their recent consensus 
regarding their defined pathology.  
What are the new findings? 
• Sessile serrated/polyps share some risk factors with conventional adenomas, and other 
risk factors are unique to sessile serrated polyps.  
• Regular use of NSAIDs is associated with a reduction in risk of sessile serrated 
adenomas/polyps in addition to conventional adenomas.  
• Red meat intake is strongly associated with increased risk of sessile serrated polyps in 
addition to conventional adenomas. 
How might it impact clinical practice in the foreseeable future? 
• Given that SSPs are difficult to detect and may accelerate to a dysplastic state quicker 
than conventional adenomas, primary prevention of sessile serrated adenomas/polyps 
through lifestyle modification may be an important strategy 
• Preventive efforts to reduce risk factors in conventional adenomas may also be 
applicable to sessile serrated adenomas/polyps.   
Keywords: Sessile serrated polyp, colorectal, adenoma, risk factors, etiology  
INTRODUCTION 
Two distinct pathways to colorectal carcinogenesis have been identified.  Well known is the 
conventional adenoma (AD)-carcinoma pathway, which involves the progression of non-
advanced tubular adenomas to larger or villous lesions with potential to develop into an invasive 
carcinoma [1].  In contrast, the more recently recognized serrated pathway is thought to 
originate from hyperplastic polyps (HPs), and transition to distinct traditional serrated adenomas 
or sessile serrated polyps (SSPs) prior to progression to dysplasia and carcinoma [2].  SSPs, 
although comprising only 4-9% of all polyps discovered on endoscopy, may represent the origin 
for 20-35% of all CRCs, particularly those with microsatellite-instable (MSI-high) or CpG-island 
methylator phenotype (CIMP-high) features [3–5].   Unlike ADs, which are diffusely distributed, 
SSPs are generally located in the proximal colon [6].  For cancer screening, their importance is 
highlighted by new data, concluding that the decline of cancer incidence over 30 years has 
corresponded primarily to distal CRC lesions, while the comparative rate of decline of proximal 
CRC is 4-7 times less [7].  Furthermore, a sizeable proportion of interval CRCs, or cancers 
discovered between appropriate CRC screening intervals, are proximal and likely to have 
originated from SSPs which have either been missed, incompletely resected, or have rapidly 
progressed to a carcinogenic state[4,8,9].   
Few studies have evaluated risk factors of SSPs due to challenges involved in their evolving 
histological definition and the relative rarity of these polyps.  For multiple reasons, studies to 
date have often clustered HPs and SSPs into a collective ‘serrated polyp’ group, despite 
differences in malignant potential between the lesions.  Similar to studies which evaluated risk 
for ADs, a few studies found risk for serrated polyps was associated with cigarette smoking [10–
14], obesity [10–12], Type II diabetes mellitus [11], a family history of CRC [12], age [11,13], 
higher education [13], and nonsteroidal anti-inflammatory drug (NSAID) use [10,14].  Even 
fewer studies have evaluated the association of dietary factors with the risk of serrated polyps.  
These studies observed that red meat intake may be associated with increased risk in distal, but 
not proximal, serrated polyps [10]. However, most of these serrated polyp studies are limited by 
the sample size and/or the likely grouping of HPs and SSPs. Given the possibility that 
endoscopy may not reduce mortality of proximal CRCs and that SSPs may be the primary 
precursor lesion for these tumors, there is a compelling need to assess modifiable lifestyle 
factors which may be associated with SSPs and to compare the associations with risk for ADs 
and HPs.    
We sought to conduct a comprehensive analysis of modifiable lifestyle risk factors which may 
affect SSP risk, and subsequently compare the associations between ADs, HPs, and SSPs.  
We utilized the Tennessee Colorectal Polyp Study (TCPS), a large case-control, colonoscopy-
based study, which has standardized assessment of SSPs, ADs, and HPs.  Our goal was to 
understand the etiology and develop a risk factor index to evaluate the joint contribution of risk 
factors to risk of SSPs and other polyps and to further compare risk factors between SSPs and 
ADs and HPs. This comparison may provide insight into the common and varied etiology of 
colorectal polyps. 
 
DESIGN 
Study design and population 
TCPS is a colonoscopy-based case-control study conducted from February 2003 to October 
2010 in Nashville, TN.  Further details regarding the methods used are previously described 
[15].  For individuals 40-75 years of age, candidacy was discussed and consent obtained if the 
subject met eligibility standards.  Ineligibility for the study was defined as any candidate having 
a history of inflammatory bowel disease (IBD) or if IBD was discovered on colonoscopy; any 
known family history of hereditary CRC syndromes; any history of cancer except for non-
melanoma skin cancer; any previous colectomy; any diagnosis of adenomas on previous 
colonoscopy or surgical resection.  Colonoscopies were conducted as part of routine care by 
trained gastroenterologists.  Institutional approval for human subjects research was granted 
through the VUMC and VA Institutional Review Boards and the VA Research and Development 
Committee.   
There were 12,585 candidates initially identified for participation in TCPS, with 7,621 
participants (60.6%) providing an informed written consent and participating in at least one 
component of the study.  A majority of participants (90.5%) were recruited prior to colonoscopy, 
and the remaining were recruited post-colonoscopy. Among the participants, 7,396 were 
diagnosed with ADs, HPs, SSPs or no polyps, and were thus eligible for this analysis. The 
current analysis is based on a total of 6,404 eligible participants (86.6%) who completed a 
telephone interview (median time to interview was 13 days). For dietary analyses, analyses 
were further limited to participants who also completed a 108-item food frequency questionnaire 
(FFQ; median time to FFQ return was 23 days) and reported daily consumption of at least 600 
kcal/day (5,398 individuals; 84.3%) [16].    
Data collection 
Following the colonoscopy, interviewers used a standard telephone interview to obtain 
information relating to the participant’s demographics, medication use, family history, and other 
lifestyle factors.  Detailed questions regarding status, intensity, duration, age of cessation, and 
age of initiation of tobacco use were asked, with current smokers defined as one cigarette 
consumed daily for each of the past six months and over 100 cigarettes within their lifetime.  
Former smokers must have quit more than one year prior to their procedure. Any reported 
smoking in the last 12 months placed them in the current smoking group.  Current alcohol use 
was defined as five or more alcoholic beverages per week over the past year. Former users did 
not meet this criteria for 12 months or greater prior to their procedure.  Body Mass Index (BMI) 
was calculated from self-reported height and weight.  Regular exercise was defined as non-
occupational exercise for at least two hours per week over a six month period within the past 
decade, with further breakdown using metabolic equivalent of task (MET) hours per week.  For 
defining current or former NSAID use, current users took NSAIDs at least three times weekly for 
the past 12 months, while former users took NSAIDs three times weekly for 12 months over the 
past 15 years, but without use within the last 12 months.  Dietary information was self-
administered using the FFQ, except in the case of red meat intake, which was obtained during 
the telephone interview in methods previously described [15].  Dietary components in the FFQ 
which were examined include daily intake of total energy (kilocalories), fiber (g/day), dietary 
folate equivalents (DFE, µg/day), calcium (mg/day), and fat (g/day) as previously described [16]. 
Classification of case groups 
All participants were recruited between 2002 and 2010, during which SSPs were not uniformly 
recognized in clinical practice, nor was a standard pathology definition developed. As a result, 
the potential for misclassification of SSPs as another type of polyp (e.g. hyperplastic) was 
substantial. To overcome this limitation of the original clinical diagnosis, we newly reviewed all 
polyps from all study participants, regardless of the initial clinical diagnosis to standardize all 
diagnoses. The study pathologist and a senior GI clinical and research pathologist established a 
consensus on application of the diagnostic criteria from expert panel standards (at least one 
distorted, dilated, or horizontally branched crypt within the polyp) by joint review of cases [3]. In 
addition, the study pathologist identified about 10% of cases in which there was a potential for 
disagreement and both pathologists reviewed those cases to reach consensus. Based on the 
pathology diagnosis, we excluded individuals who were found to have evidence of CRC (n=26) 
or traditional serrated adenomas (n=12), due to limited statistical power.  Control participants 
underwent a full colonoscopy, with evidence of reaching the cecum and complete colon 
visualization without a notation of polyps.  Visualization of the ileocecal valve and/or 
appendiceal orifice was achieved for 98.8% of polyp cases. The HP cases had one or more HPs 
without any synchronous AD or SSP. The AD cases had one or more tubular, tubulovillous, or 
villous AD with or without dysplasia and with or without synchronous HPs.  The SSP cases had 
one or more SSPs, with or without synchronous HPs and ADs.   
Statistical analysis 
Descriptive comparisons between case and control groups were calculated using general linear 
models (for continuous variables) or Mantel-Haenszel χ2 testing (for categorical variables), with 
adjustments in most comparisons for age (based on categories grouping individuals into 5-year 
age categories from 40-75), and sex.  Dietary intake quartiles were derived from intake levels 
among controls. Initial assessment of risk for case-control and case-case comparisons was 
completed using multinomial logistic regression modeling which included each case and control 
group in each model to allow direct comparison of each case group.  Models were adjusted for 
sex, age of the participant (based on the categories listed above), year of the colonoscopy, 
educational attainment, study site, cigarette smoking, and NSAID use.  Additional models, which 
included dietary factors, were adjusted for total energy intake.  In order to test for trends, we 
treated categorical variables as continuous factors in the model.  To assess whether factors had 
an independent association with polyp risk, we conducted further analysis in which factors which 
were statistically significantly associated in initial models were included in a subsequent 
multinomial logistic regression model in which they were mutually adjusted for each other.    All 
statistical analyses were completed using R Version 3.  P values of ≤0.05 (2-sided probability) 
were considered statistically significant in all analyses.     
 
RESULTS  
Demographic characteristics of each of the four groups examined (no-polyp controls, ADs, HPs, 
and SSAs) are shown in Table 1.  No significant differences were found between controls and 
case groups in comparing the procedure site, race, indication for the colonoscopy, or family 
history of CRC. Age (pheterogeneity<0.001), sex (pheterogeneity<0.001), educational attainment 
(pheterogeneity<0.001), household income (pheterogeneity=0.002) and energy intake(pheterogeneity=0.009) 
were significantly different between groups. 
  
Table 1:  Characteristics of the Study Participants, the Tennessee Colorectal Polyp Study. 
  
     
Characteristic 
No polyp 
Controls 
Hyperplastic 
Polyps 
Conventional 
Adenomas 
Sessile Serrated 
Polyps 
pheterogeneity n=3851 n=560 n=1779 n=214 
        
Study Site of Procedurea      
     Vanderbilt University MC 74.8 70 74.5 74.6 0.07 
     VA-Nashville Campus 25.2 30 25.6 25.4  
      
Age (years) 57.2 ± 7.7 56.8 ± 7.1 59.0 ± 7.4 57.8 ± 7.7 <0.001 
      
Sex (% Female) 44.8 36.4 27.5 36 <0.001 
      
Race (% Caucasian) 87 89.3 87 89.7 0.34 
      
Family History of Colorectal Cancer (%)a 9 8.6 9.4 11.9 0.44 
      
Indication for Colonoscopy (%)a      
     Average Risk Screening 56.9 54.3 55.7 57.9 0.2 
     Family History of Colorectal Cancer 12.6 13.7 12.5 16.2  
     Diagnostic/Follow Up 22.8 21.6 23.6 15.4  
     Other 7.8 10.4 8.2 10.5  
      
Educational Attainment (%)a      
     High School or Less 23.4 29.5 28.3 25 <0.001 
     Some College 28.4 28.3 28.5 27.4  
     College Graduate 21.4 21.9 22.1 27.1  
     Graduate/Professional School 26.8 20.3 21.1 20.5  
      
      
Characteristic 
No polyp 
Controls 
Hyperplastic 
Polyps 
Conventional 
Adenomas 
Sessile Serrated 
Polyps 
pheterogeneity n=3851 n=560 n=1779 n=214 
        
Household Income (%)a      
     Under $15,000 7.8 9.6 10.6 6.7 0.002 
     $15,001-$30,000 14.1 17.9 16.2 15.6  
     $30,001-$50,000 20.4 17.2 19.8 23.3  
     Over $50,000 57.7 55.3 53.5 54.4  
      
Daily Energy Intake (kcal)a 1845 1938 1912 1820 0.009 
s Standardized by age (using ages grouped into 5 year categories starting at age 40) and sex.   
Evaluation of modifiable non-dietary factors and polyp risk 
Cigarette smoking status, duration, and intensity were associated with increased polyp risk for 
all case types (Table 2).  In case-case comparisons, smoking was more strongly associated 
with SSPs than ADs for all measures of smoking (e.g. OR 1.74, 95% CI 1.16-2.62 for current vs. 
never smokers, ptrend=0.008). Obesity (BMI ≥30 kg/m2) was associated with a 30%-50% 
increased risk of polyps and risk did not significantly differ between polyp types. In comparison 
to those who never regularly used NSAIDs, current regular use of NSAIDs was associated with 
a decreased risk of SSPs (OR 0.62, 95%CI 0.62-0.85 for SSP cases vs. controls, ptrend=0.003) 
and ADs (ptrend<0.001) and but not HPs, and risk reduction was dose-dependent for years of use 
for both ADs (ptrend=0.02) and SSPs (ptrend<0.001). In addition, NSAID use of more than 10 years 
was more strongly associated with reduced risk of SSPs than ADs (OR 0.53, 95%CI 0.31-0.92 
for >10 years vs never regular use).  Use of NSAIDs more than 7 times a week were also 
associated with reduced risks of SSP and AD. Alcohol use and exercise were not associated 
with risk of any polyp type. 
  
Table 2:  Associations between Modifiable Non-Dietary Factors and Polyp Risk; the Tennessee Colorectal Polyp Study. 
Risk 
Factor 
Case-Control Comparisons  Case-Case Comparisons 
No 
polyp 
Controls 
 Hyperplastic 
Polyps 
(HP) 
 Conventional 
Adenomas 
(AD) 
 Sessile Serrated 
Polyps 
(SSP) 
 
AD vs. HP SSP vs. HP SSP vs. AD 
    
n  n OR (95% CI)a  n OR (95% CI) a  n OR (95% CI) a  OR (95% CI) a OR (95% CI) a OR (95% CI) a 
             
Cigarette Smoking Statusb 
  Never 2042  170 1.00 (ref)  685 1.00 (ref)  76 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  Former 1313  215 2.10 (1.67, 2.64)  655 1.29 (1.12, 1.49)  71 1.46 (1.01, 2.10)  0.61 (0.48, 0.79) 0.69 (0.46, 1.05) 1.13 (0.77, 1.65) 
  Current 490  175 4.60 (3.54, 5.98)  437 2.46 (2.06, 2.94)  66 4.29 (2.87, 6.40)  0.53 (0.41, 0.71) 0.93 (0.59, 1.46) 1.74 (1.16, 2.62) 
Ptrend    <0.001   <0.001   <0.001  <0.001 0.73 0.008 
               
Cigarette Smoking Duration (years)b 
  Never 2042  170 1.00 (ref)  685 1.00 (ref)  76 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  1-15 559  61 1.45 (1.06, 1.99)  207 1.08 (0.89, 1.32)  25 1.21 (0.73, 2.01)  0.75 (0.53, 1.05) 0.84 (0.47, 1.49) 1.12 (0.67, 1.89) 
  15-25 353  71 2.61 (1.91, 3.58)  166 1.26 (1.01, 1.57)  19 1.29 (0.72, 2.32)  0.48 (0.34, 0.68) 0.49 (0.26, 0.94) 1.02 (0.56, 1.86) 
  25-35 392  92 3.09 (2.31, 4.15)  252 1.85 (1.51, 2.25)  40 3.18 (2.06, 4.91)  0.60 (0.44, 0.82) 1.03 (0.63, 1.69) 1.72 (1.11, 2.69) 
  >35 498  166 4.73 (3.59, 6.22)  462 2.28 (1.90, 2.73)  52 3.30 (2.87, 5.08)  0.53 (0.41, 0.71) 0.70 (0.43, 1.13) 1.45 (0.94, 2.24) 
Ptrend    <0.001   <0.001   <0.001  <0.001 0.28 0.03 
               
Cigarette Smoking Intensity (pack-years)b 
  Never 2042  170 1.00 (ref)  685 1.00 (ref)  76 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  1-9 588  83 1.94 (1.46, 2.59)  239 1.32 (1.09, 1.59)  31 1.55 (0.97, 2.46)  0.68 (0.50, 0.93) 0.80 (0.47, 1.34) 1.17 (0.73, 1.89) 
  10-29 588  142 3.12 (2.41, 4.04)  297 1.32 (1.10, 1.58)  36 1.76 (1.13, 2.75)  0.42 (0.32, 0.56) 0.56 (0.34, 0.92) 1.34 (0.85, 2.11) 
Risk 
Factor 
Case-Control Comparisons  Case-Case Comparisons 
No 
polyp 
Controls 
 Hyperplastic 
Polyps 
(HP) 
 Conventional 
Adenomas 
(AD) 
 Sessile Serrated 
Polyps 
(SSP) 
 
AD vs. HP SSP vs. HP SSP vs. AD 
    
n  n OR (95% CI)a  n OR (95% CI) a  n OR (95% CI) a  OR (95% CI) a OR (95% CI) a OR (95% CI) a 
  ≥30 651  164 3.18 (2.43, 4.16)  549 2.10 (1.77, 2.48)  69 3.21 (2.14, 4.81)  0.66 (0.50, 0.87) 1.01 (0.63, 1.60) 1.53 (1.01, 2.31) 
Ptrend    <0.001   <0.001   <0.001  <0.001 0.70 0.04 
               
Recency of Cigarette Smoking (years)b 
  Current 490  175 1.00 (ref)  437 1.00 (ref)  66 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  Quit <10 245  63 0.67 (0.48, 0.94)  158 0.71 (0.55, 0.91)  13 0.38 (0.20, 0.71)  1.06 (0.75, 1.52) 0.57 (0.29, 1.12) 0.54 (0.28, 1.01) 
  Quit 10-20 307  69 0.64 (0.46, 0.88)  174 0.60 (0.47, 0.76)  24 0.55 (0.33, 0.91)  0.94 (0.67, 1.33) 0.86 (0.49, 1.51) 0.91 (0.54, 1.53) 
  Quit >20 761  83 0.29 (0.22, 0.40)  323 0.42 (0.35, 0.52)  34 0.24 (0.15, 0.39)  1.44 (1.04, 1.99) 0.81 (0.47, 1.40) 0.56 (0.34, 0.92) 
  Never 2042  170 0.21 (0.16, 0.27)  685 0.40 (0.33, 0.48)  76 0.23 (0.15, 0.34)  1.90 (1.44, 2.50) 1.08 (0.69, 1.70) 0.57 (0.38, 0.86) 
Ptrend    <0.001   <0.001   <0.001  <0.001 0.63 0.009 
               
Regular Alcohol Useb,c 
  Never 2286  284 1.00 (ref)  893 1.00 (ref)  111 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  Former 831  145 0.87 (0.68, 1.11)  505 1.02 (0.87, 1.20)  50 0.89 (0.60, 1.32)  1.17 (0.90-1.51) 1.02 (0.66-1.58) 0.87 (0.59-1.30) 
  Current 720  130 1.12 (0.88, 1.43)  378 1.03 (0.87, 1.21)  53 1.06 (0.72, 1.56)  0.91 (0.71-1.19) 0.94 (0.61-1.46) 1.03 (0.69-1.53) 
Ptrend    0.49   0.74   0.86  0.66 0.81 0.97 
               
Body Mass Index (kg/m2) b,c 
  18.0-24.9 1201  143 1.00 (ref)  446 1.00 (ref)  58 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  25.0-29.9 1443  201 1.06 (0.83, 1.35)  710 1.14 (0.97, 1.33)  83 1.22 (0.84, 1.79)  1.07 (0.83-1.39) 1.16 (0.75-1.78) 1.08 (0.73-1.59) 
Risk 
Factor 
Case-Control Comparisons  Case-Case Comparisons 
No 
polyp 
Controls 
 Hyperplastic 
Polyps 
(HP) 
 Conventional 
Adenomas 
(AD) 
 Sessile Serrated 
Polyps 
(SSP) 
 
AD vs. HP SSP vs. HP SSP vs. AD 
    
n  n OR (95% CI)a  n OR (95% CI) a  n OR (95% CI) a  OR (95% CI) a OR (95% CI) a OR (95% CI) a 
  >30.0 1189  215 1.49 (1.17, 1.90)  611 1.34 (1.13, 1.57)  72 1.51 (1.02, 2.24)  0.90 (0.69-1.16) 1.02 (0.66-1.58) 1.13 (0.76-1.69) 
Ptrend    <0.001   <0.001   0.04  0.34 0.98 0.55 
               
Regular Exerciseb,c 
  No 1606  266 1.00 (ref)  863 1.00 (ref)  58 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  Yes 2245  294 0.96 (0.79, 1.16)  916 0.90 (0.79, 1.02)  83 0.91 (0.67, 1.24)  0.94 (0.76-1.16) 0.95 (0.67-1.34) 1.01 (0.74-1.39) 
Ptrend    0.67   0.11   0.55  0.34 0.77 0.94 
               
Regular Exercise Intensity (MET hours per week) b,c 
  0.1-10.5 558  80 1.00 (ref)  235 1.00 (ref)  26 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  10.5-21.0 565  73 0.98 (0.69, 1.40)  248 1.05 (0.83, 1.33)  34 1.11 (0.62, 2.00)  1.07 (0.73, 1.56) 1.13 (0.59, 2.17) 1.06 (0.58, 1.92) 
  21.0-36.2 558  71 0.90 (0.62, 1.28)  208 0.92 (0.72, 1.17)  31 1.29 (0.73, 2.27)  1.03 (0.69, 1.51) 1.44 (0.76, 2.72) 1.40 (0.78, 2.51) 
  >36.2 563  68 0.83 (0.58, 1.19)  222 0.91 (0.72, 1.16)  23 0.82 (0.44, 1.53)  1.10 (0.74, 1.63) 0.99 (0.50, 1.98) 0.90 (0.48, 1.70) 
Ptrend    0.27   0.30   0.71  0.69 0.78 0.96 
               
Regular NSAID Usec 
  Never 1698  241 1.00 (ref)  744 1.00 (ref)  103 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  Former 245  33 0.89 (0.60, 1.33)  108 0.97 (0.75, 1.25)  11 0.72 (0.38, 1.37)  1.09 (0.71-1.66) 0.81 (0.39-1.67) 0.74 (0.38-1.44) 
  Current 1881  267 0.92 (0.76, 1.12)  784 0.79 (0.69, 0.90)  82 0.62 (0.46, 0.85)  0.86 (0.69-1.05) 0.68 (0.48-0.96) 0.79 (0.57-1.09) 
Ptrend    0.41   <0.001   0.003  0.14 0.03 0.15 
               
Risk 
Factor 
Case-Control Comparisons  Case-Case Comparisons 
No 
polyp 
Controls 
 Hyperplastic 
Polyps 
(HP) 
 Conventional 
Adenomas 
(AD) 
 Sessile Serrated 
Polyps 
(SSP) 
 
AD vs. HP SSP vs. HP SSP vs. AD 
    
n  n OR (95% CI)a  n OR (95% CI) a  n OR (95% CI) a  OR (95% CI) a OR (95% CI) a OR (95% CI) a 
Duration of Regular NSAID Use (years)c 
  0-<1 1698  241 1.00 (ref)  744 1.00 (ref)  103 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
  1-5 979  122 0.83 (0.65, 1.05)  374 0.78 (0.66, 0.91)  48 0.76 (0.53, 1.09)  0.94 (0.73, 1.21) 0.92 (0.61, 1.38) 0.98 (0.67, 1.41) 
  6-10 618  106 1.11 (0.86, 1.44)  272 0.85 (0.71, 1.01)  27 0.62 (0.39, 0.97)  0.76 (0.58, 1.00) 0.56 (0.34, 0.91) 0.73 (0.46, 1.16) 
  >10 529  73 0.86 (0.64, 1.15)  246 0.81 (0.67, 0.98)  18 0.43 (0.25, 0.74)  0.95 (0.69, 1.29) 0.50 (0.28, 0.91) 0.53 (0.31, 0.92) 
Ptrend    0.70   0.02   <0.001  0.26 0.004 0.01 
               
Dose of Regular NSAID Use (times per week)c 
0 1588  242 1.00 (ref)  832 1.00 (ref)  115 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
<7 304  45 1.01 (0.71-1.43)  106 0.79 (0.62-1.02)  11 0.56 (0.29-1.07)  0.79 (0.54-1.16) 0.56 (0.28-1.13) 0.71 (0.37-1.37) 
7 965  137 0.92 (0.72-1.17)  453 0.83 (0.71-0.97)  55 0.77 (0.54-1.10)  0.90 (0.70-1.16) 0.84 (0.56-1.26) 0.93 (0.65-1.34) 
>7 994  136 0.86 (0.67-1.09)  388 0.75 (0.64-0.88)  33 0.48 (0.32-0.73)  0.88 (0.68-1.13) 0.57 (0.36-0.90) 0.64 (0.42-0.98) 
Ptrend    0.19   <0.001   0.001  0.30 0.03 0.08 
a Derived from multinomial logistic regression models which included all case and controls groups and adjusted for age (40-49, 50-59, 
60-64, and 65+ years of age), sex, educational attainment, year of colonoscopy, and study site 
b Additionally adjusted for NSAID use 
c Additionally adjusted for cigarette smoking status 
Evaluation of modifiable dietary factors and polyp risk    
Higher daily dietary intake of fiber was associated with a reduced risk of SSPs (OR 0.36, 95% 
CI 0.19-0.68 for highest vs. lowest intake quartile, ptrend=0.006) but was not statistically 
significantly different between SSPs and ADs (Table 3). Folate intake (DFE) was associated 
with an approximate 50% reduction in risk for all polyp types. Calcium intake was only 
associated with statistically significantly reduced risks of ADs and HPs, and was not associated 
with a statistically significantly reduced risk of SSPs although the associations were in the same 
direction and of similar magnitude. However, risk was not statistically significantly different 
between any of the case groups. Fat intake was associated with a strong dose-dependent 
three-fold increased risk of SSPs in comparison to controls (OR 3.09, 95% CI 1.24-7.72 for 
highest vs. lowest intake quartile, ptrend=0.01) and AD cases (OR 3.20, 95% CI 1.26-8.12 for 
highest vs. lowest intake quartile, ptrend=0.02).   Higher red meat intake was associated with all 
types of polyp risk, but displayed a particularly strong association with SSP risk (OR 3.38, 95% 
CI 1.90-6.00 for highest vs. lowest intake quartile, ptrend<0.001). In case-case comparisons, SSP 
risk was approximately two-fold greater than risks of either ADs or HPs for individuals 
consuming higher red meat intakes. 
  
Table 3:  Associations between Modifiable Dietary Factors and Polyp Risk; the Tennessee Colorectal Polyp Study. 
Dietary 
Intake 
(per day) 
Case-Control Comparisons  Case-Case Comparisons 
No 
polyp 
Controls 
 Hyperplastic 
Polyps 
(HP) 
 Conventional 
Adenomas 
(AD) 
 Sessile Serrated 
Adenoma/Polyps 
(SSP) 
 
AD vs. HP SSP vs. HP SSP vs. AD 
    
n  n OR (95% CI)  n OR (95% CI)  n OR (95% CI)  OR (95% CI) OR (95% CI) OR (95% CI) 
             
Fiber (g)a 
   2.91-12.88 813  114 1.00 (ref)  375 1.00 (ref)  57 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
   12.88-17.79 811  127 1.01 (0.75, 1.38)  319 .072 (0.58, 0.89)  47 0.50 (0.30, 0.82)  0.71 (0.51, 0.99) 0.49 (0.28, 0.86) 0.69 (0.41, 1.15) 
   17.79-24.73 811  113 0.81 (0.57, 1.15)  380 0.75 (0.59, 0.94)  37 0.64 (0.38, 1.08)  0.92 (0.64, 1.34) 0.79 (0.43, 1.44) 0.85 (0.50, 1.46) 
   >24.73 811  118 0.71 (0.48, 1.05)  428 0.65 (0.50, 0.85)  47 0.46 (0.19, 0.68)  0.92 (0.60, 1.40) 0.51 (0.25, 1.04) 0.56 (0.29, 1.06) 
Ptrend    0.05   0.004   0.006  0.96 0.17 0.12 
               
Dietary Folate Equivalents (µg)a 
   63.8-394.7 812  119 1.00 (ref)  369 1.00 (ref)  48 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
   394.7-572.6 811  123 0.88 (0.64, 1.21)  348 0.74 (0.59, 0.91)  48 0.99 (0.60, 1.65)  0.83 (0.59, 1.18) 1.12 (0.64, 1.99) 1.35 (0.80, 2.26) 
   572.6-811.8 811  119 0.68 (0.47, 0.97)  380 0.64 (0.50, 0.81)  46 0.83 (0.47, 1.47)  0.94 (0.64, 1.38) 1.23 (0.65, 2.32) 1.30 (0.73, 2.33) 
   >811.8 812  111 0.53 (0.35, 0.80)  405 0.56 (0.43, 0.73)  36 0.51 (0.26, 0.98)  1.05 (0.68, 1.61) 0.96 (0.46, 2.00) 0.91 (0.47, 1.78) 
Ptrend    <0.001   <0.001   0.03  0.62 0.94 0.69 
               
Calcium (mg)a 
   128.0-595.8 812  118 1.00 (ref)  370 1.00 (ref)  53 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
   595.8-837.8 811  117 0.91 (0.66, 1.26)  342 0.80 (0.65, 1.00)  32 0.70 (0.42, 1.19)  0.88 (0.63, 1.24) 0.77 (0.43, 1.38) 0.87 (0.51, 1.50) 
   837.8-1217 811  112 0.68 (0.47, 0.99)  390 0.68 (0.54, 0.88)  55 0.99 (0.56, 1.76)  1.00 (0.67, 1.48) 1.45 (0.76, 2.76) 1.45 (0.81, 2.59) 
Dietary 
Intake 
(per day) 
Case-Control Comparisons  Case-Case Comparisons 
No 
polyp 
Controls 
 Hyperplastic 
Polyps 
(HP) 
 Conventional 
Adenomas 
(AD) 
 Sessile Serrated 
Adenoma/Polyps 
(SSP) 
 
AD vs. HP SSP vs. HP SSP vs. AD 
    
n  n OR (95% CI)  n OR (95% CI)  n OR (95% CI)  OR (95% CI) OR (95% CI) OR (95% CI) 
   >1217 812  125 0.66 (0.44, 0.99)  400 0.57 (0.43, 0.75)  38 0.54 (0.28, 1.06)  0.86 (0.56, 1.33) 0.83 (0.40, 1.74) 0.96 (0.49, 1.88) 
Ptrend    0.03   <0.001   0.13  0.64 0.90 0.88 
               
Fat (g)a 
   11.91-48.00 812  91 1.00 (ref)  299 1.00 (ref)  38 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
   48.00-68.06 810  110 1.24 (0.85, 1.80)  293 0.85 (0.66, 1.09)  36 1.40 (0.77, 2.55)  0.69 (0.46, 1.03) 1.13 (0.57, 2.22) 1.64 (0.88, 3.04) 
   68.06-98.16 812  126 1.23 (0.77, 1.95)  386 0.89 (0.66, 1.21)  44 2.32 (1.07, 5.04)  1.00 (0.44, 1.19) 1.89 (0.80, 4.50) 2.60 (1.18, 5.76) 
   >98.16 812  145 1.19 (0.69, 2.06)  524 0.97 (0.67, 1.39)  60 3.09 (1.24, 7.72)  0.86 (0.45, 1.46) 2.61 (0.94, 7.23) 3.20 (1.26, 8.12) 
Ptrend    0.62   0.99   0.01  0.64 0.05 0.02 
               
Red Meat (g)a 
   0-16.06 811  73 1.00 (ref)  226 1.00 (ref)  25 1.00 (ref)  1.00 (ref) 1.00 (ref) 1.00 (ref) 
   16.06-38.54 809  112 1.53 (1.10, 2.12)  358 1.42 (1.15, 1.76)  33 1.42 (0.79, 2.57)  0.93 (0.65, 1.33) 0.93 (0.48, 1.79) 1.00 (0.55, 1.83) 
   38.54-73.38 807  123 1.51 (1.08, 2.10)  360 1.36 (1.10, 1.69)  47 2.32 (1.32, 4.08)  0.90 (0.63, 1.30) 1.54 (0.82, 2.90) 1.70 (0.95, 3.04) 
   >73.38 808  163 1.68 (1.19, 2.37)  552 1.67 (1.34, 2.09)  73 3.38 (1.90, 6.00)  1.00 (0.69, 1.44) 2.02 (1.06, 3.83) 2.02 (1.13, 3.63) 
Ptrend    0.009   <0.001   <0.001  0.93 0.006 0.003 
a Derived from multinomial logistic regression models which included all case and controls groups and adjusted for age based on 
categories (ages 40-49, 50-59, 60-64, and 65+) sex, educational attainment, year of colonoscopy, study site, cigarette use, NSAID 
use status, and total daily energy intake (divided into quartile categories based on kilocalories/day). 
Evaluation of independent associations 
To evaluate which factors in Tables 2 and 3 were independently associated with polyp risk after 
mutual adjustment, we conducted an analysis in which factors which were statistically 
significantly associated with risk of any polyp type were included in a single multinomial logistic 
regression model (Table 4).  After adjustment for other factors, SSP risk was no longer 
statistically significant for obesity and fiber, folate, and fat intakes although fiber intake was 
associated with a borderline statistically significant reduced SSP.  Conversely, several 
associations persisted after adjustment.  Smoking remained strongly associated with risk of all 
polyps.  NSAID use and red meat intake were associated with SSP risk.  
  
Table 4:  Evaluation of Independent Associations between Modifiable Factors and Polyp Risk, the Tennessee 
Colorectal Polyp Study  
Factor 
No 
  
Hyperplastic   Conventional 
  
Sessile Serrated 
polyp Polyps  Adenomas Adenoma/Polyps 
Controls (HP)   (AD) (SSP) 
n   n OR (95% CI)a   n OR (95% CI)a   n OR (95% CI)a 
Cigarette Smoking          
   Never 1774  147 1.00 (ref)  596 1.00 (ref)  63 1.00 (ref) 
   Former 1126  190 2.22 (1.73, 2.85)  550 1.24 (1.06, 1.45)  60 1.41 (0.94, 2.10) 
   Current 343  190 5.06 (3.75, 6.82)  355 2.68 (2.19, 3.29)  54 4.68 (2.99, 7.31) 
Ptrend    <0.001   <0.001   <0.001 
           
Body Mass Index (kg/m2)          
   18.0 – 24.9 1049  120 1.00 (ref)  389 1.00 (ref)  49 1.00 (ref) 
   25.0 – 29.9 1224  174 1.05 (0.80, 1.37)  600 1.07 (0.90, 1.27)  70 1.15 (0.76, 1.74) 
   >30 965  178 1.43 (1.09, 1.88)  506 1.23 (1.02, 1.48)  59 1.25 (0.80, 1.94) 
Ptrend    0.007   0.03   0.33 
           
Regular NSAID Use          
   Never 1438  197 1.00 (ref)  633 1.00 (ref)  83 1.00 (ref) 
   Former 206  29 0.96 (0.62-1.48)  88 0.92 (0.69, 1.23)  8 0.68 (0.32, 1.46) 
   Current 1593  228 0.90 (0.73, 1.13)  679 0.77 (0.66, 0.89)  75 0.68 (0.48, 0.96) 
Ptrend    0.36   <0.001   0.03 
           
           
           
Factor 
No 
  
Hyperplastic   Conventional 
  
Sessile Serrated 
polyp Polyps  Adenomas Adenoma/Polyps 
Controls (HP)   (AD) (SSP) 
n   n OR (95% CI)a   n OR (95% CI)a   n OR (95% CI)a 
Fiber Intake (g/day)          
   2.91 – 12.88 813  114 1.00 (ref)  375 1.00 (ref)  57 1.00 (ref) 
   12.88 – 17.79 811  127 1.16 (0.83, 1.63)  319 0.83 (0.66, 1.05)  37 0.47 (0.27, 0.82) 
   17.79 – 24.73 811  113 1.05 (0.70, 1.58)  380 0.95 (0.73, 1.24)  47 0.63 (0.34, 1.17) 
   24.73 – 126.3 811  118 1.09 (0.68, 1.76)  428 0.93 (0.68, 1.28)  37 0.47 (0.22, 1.01) 
Ptrend    0.85   0.92   0.11 
           
Dietary Folate Equivalents Intake (µg/day)    
   63.81 – 394.7 812  119 1.00 (ref)  369 1.00 (ref)  48 1.00 (ref) 
   394.7 – 572.6 811  123 0.86 (0.60, 1.23)  348 0.82 (0.64, 1.04)  48 1.37 (0.78, 2.43) 
   572.6 – 811.8 811  119 0.70 (0.45, 1.07)  380 0.74 (0.55, 0.98)  46 1.26 (0.63, 2.53) 
   811.8 - 4542 812  111 0.57 (0.34, 0.95)  405 0.71 (0.50, 0.99)  36 1.00 (0.44, 2.29) 
Ptrend    0.03   0.05   0.9 
           
Dietary Calcium Intake (mg/day)    
   128.0 – 595.8 812  118 1.00 (ref)  370 1.00 (ref)  53 1.00 (ref) 
   595.8 – 837.8 811  117 0.98 (0.70, 1.37)  342 0.91 (0.72, 1.14)  32 0.74 (0.42, 1.29) 
   837.8 – 1217 811  112 0.83 (0.56, 1.24)  390 0.81 (0.61, 1.06)  55 1.10 (0.59, 2.05) 
   1217 – 6880 812  125 0.86 (0.55, 1.35)  400 0.68 (0.50, 0.92)  38 0.70 (0.33, 1.45) 
Ptrend    0.44   0.01   0.47 
           
           
           
Factor No   Hyperplastic   Conventional   Sessile Serrated 
polyp Polyps  Adenomas Adenoma/Polyps 
Controls (HP)   (AD) (SSP) 
n   n OR (95% CI)a   n OR (95% CI)a   n OR (95% CI)a 
Total Fat Intake (g/day)          
   11.91 – 48.00 812  91 1.00 (ref)  299 1.00 (ref)  38 1.00 (ref) 
   48.00 – 68.06 810  110 1.12 (0.76, 1.64)  293 0.80 (0.62, 1.04)  36 1.30 (0.70, 2.42) 
   68.06 – 98.16 812  126 0.98 (0.60, 1.59)  386 0.76 (0.55, 1.05)  44 1.79 (0.79, 4.04) 
   98.16 – 377.4 812  145 0.89 (0.49, 1.60)  524 0.80 (0.55, 1.19)  60 2.15 (0.81, 5.69) 
Ptrend    0.58   0.32   0.13 
           
Red Meat Intake (g/day)    
   0.0 – 16.07 811  73 1.00 (ref)  226 1.00 (ref)  25 1.00 (ref) 
   16.07 – 38.54 809  112 1.46 (1.04, 2.03)  358 1.38 (1.11, 1.71)  33 1.30 (0.71, 2.36) 
   38.54 – 73.88 807  123 1.38 (0.98, 1.96)  360 1.28 (1.03, 1.61)  47 1.90 (1.06, 3.41) 
   73.88 – 625.8 808  163 1.48 (1.03, 2.14)  552 1.53 (1.21, 1.94)  73 2.59 (1.41, 4.74) 
Ptrend       0.08     0.002     <0.001 
a Derived from multinomial logistic regression models which included all case and controls groups and adjusted for 
age (40-49, 50-59, 60-64, and 65+ years of age), sex, educational attainment, year of colonoscopy, study site, and 
total daily energy intake (divided into quartile categories based on kilocalories/day). Additionally adjusted for all 
variables within the table. 
DISCUSSION 
This analysis assesses modifiable lifestyle risk factors in a screening colonoscopy-age 
population to evaluate risk factors for SSP and to compare them with other common colorectal 
polyps.  Given the recent identification within the past 1-2 decades of SSPs as a CRC 
precursor, we are still in the infancy of understanding the etiology of these lesions and which 
risk factors may be associated with these polyps.  With their importance in the pathways’ 
underlying progression to cancer and the relative difficulty in identification on colonoscopy, 
finding ways to assess risk in a population are of utmost importance.  This is the first study to 
evaluate dietary intake with risk for SSPs and one of the largest epidemiologic studies to date of 
SSPs. We newly found that red meat, fat, and fiber intakes were associated with SSP risk, and 
we also confirmed previous findings of associations with cigarette smoking and with NSAID use, 
and a lack of association with alcohol use.  
Unlike a consistent association with polyp risk [14,17], cigarette smoking has been modestly 
and inconsistently associated with CRC risk [18].  One possible reason for the inconsistency in 
past studies is a mixing of the types of CRC tumors which have different associations. Recent 
studies have more consistently identified smoking as a risk factor of MSI-high or CIMP-high 
CRC tumors which are part of the serrated pathway [19,20].  Indeed, cigarette smoking is 
strongly and consistently associated with risk of serrated polyps, including in this study [3,10–
14,21].  Smoking cessation has many benefits for health and we found cessation as short as 10 
years was associated with decreased risk of all polyps compared to current smokers. Further, 
after cessation for more than 20 years, risk was similar to never smokers. This relationship was 
particularly strong for SSPs vs. ADs. 
NSAIDs and aspirin use may be an approach for colorectal neoplasia prevention; however, very 
little is known regarding NSAIDs and their association with SSP risk [10,13,22,23].   A previous 
study of serrated polyps found an inverse association between aspirin use and serrated polyp 
risk which was particularly strong for proximal lesions [10].  In the only previous study to 
evaluate SSP risk, regular NSAID use was associated with reduced risk. We also observed this 
[13].  We also found the reduction in risk associated with more than 10 years of use was 
stronger for SSPs than for ADs. The absence of an association with HP risk and the presence of 
an association with SSP risk may provide insight into the etiology of SSPs and may be a 
distinguishing factor in inhibiting transition from HP to SSP.  Thus, NSAID use may hold promise 
as a chemopreventive strategy for SSPs and should be evaluated in future studies.  
Body composition and exercise are well studied modifiable factors evaluated in AD and CRC 
risk [24,25].  An association between SSP risk and obesity is currently equivocal [10–13].  
Although we observed a statistically significant association between BMI-defined obesity and 
colorectal polyp risk in all case groups, after adjustment for other factors, a statistically 
significant association was no longer observed for SSP risk. Interestingly, no association was 
observed for physical activity measures, including a measure of intensity and duration (MET 
hours). Both of these findings are consistent with a previous study which found no association 
between either BMI or hours of exercise with SSPs risk [13].    
Dietary fiber has been speculated to protect against polyp formation by bulking the stool and 
increasing transit time, which may decrease the surface area of the colon exposed to 
carcinogenic toxins and bile acids within fecal matter [31].   Although we initially observed 
decreased risks of adenomas with fiber intake, these associations did not persist in subsequent 
models after adjustment for other risk factors. However, a suggestive borderline significant 
inverse association was observed with highest fiber intake and SSP risk. Future studies with a 
larger sample size are needed to confirm this finding. Likewise, both calcium and folate intakes 
initially appeared to be associated with decreased risk of SSPs However, the associations 
disappeared after adjustment for other factors. Thus, this study does not support a strong 
relationship between calcium or folate intakes with SSP risk (although these factors should be 
evaluated in future larger studies). This result is also consistent with the findings from recent 
randomized trials in which supplementation of calcium or folic acid have not successfully 
decreased risk of AD recurrence [32–35].   
Red meat intake is consistently reported as a risk factor for CRC and colorectal adenomas 
[36,37], although it has not previously been known whether an association exists between red 
meat intake and  SSP risk. Risk of MSI-high CRC, for which SSPs are the presumed precursor 
lesion, is increased with well-done red meat intake, suggesting a possible role of red meat 
intake in SSP risk [38].  Consistent with this finding, we found, for the first time, that high 
consumption of red meat was strongly associated with SSP risk.  Interestingly, we also found 
that higher dietary fat intake was associated with risk of SSPs but not ADs or HPs; however, this 
relationship did not maintain statistical significance after adjustment for other risk factors. These 
included red meat intake, which may have been due to our sample size, over adjustment, or 
may suggest that the fat intake association is a potential measure of red meat intake.  Previous 
studies of serrated polyps have observed an association between high fat diet and serrated 
polyp risk, although this was not specific to SSPs [10].  The potential mechanism behind an 
association is unclear, and further studies are needed. 
There are several strengths within this study.  To date, it is one of only two large studies 
evaluating modifiable lifestyle risk factors for SSPs, and is the first study to evaluate dietary risk 
factors for SSPs [13].  We were able to rigorously standardize the diagnosis of all polyps 
regardless of initial clinical diagnosis using recently developed standards for HPs, ADs, and 
SSPs and our observed prevalence of SSPs was consistent with recent prevalence studies 
[3,39]. We were able to comprehensively evaluate several different modifiable factors.  
There are also weaknesses in this study, which we attempted to limit. As with all case-control 
studies, we cannot exclude the possibility of recall bias although it may have been minimized 
because colorectal polyps are a benign diagnosis and the data collection period was short. 
Recent studies have indicated that several factors may contribute to detection rates of polyps 
including quality of the bowel cleansing and withdrawal time[40].  We did not collect data on 
these factors and so cannot exclude the possibility of missed polyps which may have resulted in 
case misclassification. Given that SSPs are relatively rare, our SSP case group also included 
individuals with synchronous ADs (43%), which could potentially have affected the results if the 
risk factor was associated with ADs and not SSAs. However, we also observed associations 
that were only present for SSP risk, suggesting that we were able to evaluate risk factors for 
SSP. We did perform sensitivity analysis by examining individuals SSPs who did not have any 
Ads (supplemental tables).  Although this diminished statistical power, we observed very similar 
results for all factors analyzed as we observed when including individuals with ADs in the SSP 
case group, thus, indicating that the presence of an AD was not likely driving the observed 
associations. We may have failed to detect an association because statistical power in some of 
the subgroup analyses could have been limited. Thus, future larger studies are needed. 
Although this study included individuals with a wide range of characteristics and behaviors and 
we observed associations which both increased or decreased risk, we cannot exclude the 
possibility that individuals who receive colonoscopies are different in ways from individuals who 
do not receive colonoscopies which may affect the observed associations in an unknown 
manner.  
In summary, this study provides an extensive evaluation of lifestyle risk factors for SSPs and a 
comparison of risk for SSPs with risks for ADs and HPs. Given that SSPs are difficult to detect 
and fully remove on endoscopic screening and may accelerate to a dysplastic state quicker than 
ADs [4,8,9,41–43], primary prevention of SSPs through lifestyle modification may be an 
important strategy.  The study found that many of the same risk factors are shared between 
ADs, HPs, and SSPs.  Thus, preventive efforts to reduce risk factors in ADs may also be 
applicable to SSPs.  The study also found some differences in risk factors between the polyp 
types. Larger studies of SSPs will be needed to confirm these findings and future studies should 
also evaluate potential interactions of these risk factors with genetic or molecular risk factors, as 
well as preventive strategies that may be unique to SSPs. 
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